Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomarker qualification

Executive Summary

Verbal feedback from FDA on a package of nephrotoxicity biomarkers submitted by a consortium of drug companies "has been quite positive, so we expect a good read," Critical Path Institute CEO Raymond Woosley tells "The Pink Sheet." The agency is reviewing data on seven biomarkers as part of a pilot program to determine how to qualify biomarkers for specific uses. Data indicate they are "far more sensitive and can pick up injury much earlier and with much greater specificity" than existing indicators of kidney disease, he says. The same firms are planning a clinical trial "to get these not just used in drug development, but used in medicine," Woosley says. The consortium operates under the auspices of C-Path (1"The Pink Sheet" July 9, 2007, p. 3)...

You may also be interested in...

Nephrotoxicity Biomarkers To Be Test Run For FDA Qualification Program

ATLANTA - A set of nephrotoxicity biomarkers will be the first submission considered by an FDA pilot program for qualifying biomarkers

Formycon’s Lucentis Biosimilar Enters Swiss and Canada Markets

Switzerland and Canada mark the first market entries for Formycon’s ranibizumab biosimilar this year, with several anticipated launches in the Middle East later in 2024.

Pipeline Watch: Six Approvals And 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts